11-hydroxy-n-(n-propyl)noraporphine has been researched along with Dyskinesia, Drug-Induced in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S | 1 |
| Fisher, R; Jackson, MJ; Jenner, P; Lees, AJ; Lincoln, L; Neumeyer, J; Rose, S; Sromek, AW | 1 |
1 review(s) available for 11-hydroxy-n-(n-propyl)noraporphine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.
Topics: Animals; Apomorphine; Aporphines; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Male; MPTP Poisoning; Valerates | 2016 |
1 other study(ies) available for 11-hydroxy-n-(n-propyl)noraporphine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Stereoisomerism; Structure-Activity Relationship; Thioctic Acid | 2011 |